Extended susceptibility testing for refractory Helicobacter pylori infection: regional testing should guide antimicrobial decision making
Abstract
BACKGROUND: Helicobacter pylori (H. pylori) is a Gram-negative bacterium and common cause of gastritis. Antimicrobial treatment typically involves two agents and is prescribed empirically however therapy can be complicated by drug allergies or previous, unsuccessful regimens. Recent data from Europe suggests rising resistance to commonly used agents but contemporary data relevant to UK populations, particularly following the COVID-19 pandemic is limited. This study aimed to report susceptibility testing results in refractory cases of H. pylori infections to evaluate local resistance patterns, inform treatment strategies, and compare findings with data from the European Registry on H. pylori management. METHODS: A retrospective multi-centre cohort study was conducted between September 2018 and September 2023 at North West London Pathology (London, UK), a central laboratory operating through a hub and spoke model, to assess extended antimicrobial susceptibilities in gastric biopsy samples from patients with refractory H. pylori infection. Antimicrobial susceptibilities were assessed using minimum inhibitory concentration methods as per contemporaneous European Committee on Antimicrobial Susceptibility Testing guidelines. Results were compared with European data. RESULTS: A total of 193 individual isolates were identified. Mean resistance rates were low for tetracycline (2.3%) and amoxicillin (7.3%), moderately low for rifampicin (14.0%), moderate for levofloxacin (27.3%) and…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.